Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Emerging migraine treatments and drug targets

Research output: Contribution to journalReviewResearchpeer-review

  1. High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Novel Targeted Therapies for Inflammatory Bowel Disease

    Research output: Contribution to journalReviewResearchpeer-review

  3. Heteromeric α7β2 Nicotinic Acetylcholine Receptors in the Brain

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Interstitial cells of Cajal as targets for pharmacological intervention in gastrointestinal motor disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Meningeal contribution to migraine pain: a magnetic resonance angiography study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Nosographic analysis of osmophobia and field testing of diagnostic criteria including osmophobia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sildenafil and calcitonin gene-related peptide dilate intradural arteries: A 3T MR angiography study in healthy volunteers

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Migraine has a 1-year prevalence of 10% and high socioeconomic costs. Despite recent drug developments, there is a huge unmet need for better pharmacotherapy. In this review we discuss promising anti-migraine strategies such as calcitonin gene-related peptide (CGRP) receptor antagonists and 5-hydroxytrypamine (5-HT)(1F) receptor agonists, which are in late-stage development. Nitric oxide antagonists are also in development. New forms of administration of sumatriptan might improve efficacy and reduce side effects. Botulinum toxin A has recently been approved for the prophylaxis of chronic migraine. Tonabersat, a cortical spreading depression inhibitor, has shown efficacy in the prophylaxis of migraine with aura. Several new drug targets such as nitric oxide synthase, the 5-HT(1D) receptor, the prostanoid receptors EP(2) and EP(4), and the pituitary adenylate cyclase receptor PAC1 await development. The greatest need is for new prophylactic drugs, and it seems likely that such compounds will be developed in the coming decade.
Original languageEnglish
JournalTrends in Pharmacological Sciences
Volume32
Issue number6
Pages (from-to)352-9
Number of pages8
ISSN0165-6147
DOIs
Publication statusPublished - 2011

    Research areas

  • Benzamides, Benzopyrans, Botulinum Toxins, Type A, Drug Design, Drug Therapy, Humans, Migraine Disorders, Nervous System, Nitric Oxide, Receptors, Calcitonin Gene-Related Peptide, Serotonin 5-HT1 Receptor Agonists, Sumatriptan

ID: 34669477